RHS Ltd was founded to develop advanced patented single cell genomic technologies. These technologies originated from the Department of Obstetrics and Gynaecology at The University of Adelaide. RHS founding scientists wrote one of the first papers on the use of microarrays for Pre-implantation Genetic Screening in 2004 1 & 2. The research published in that paper formed the basis for patents and exclusive licences to RHS in Australia, the USA, Europe, China, New Zealand and Canada.
Since its inception, RHS has maintained a consistent focus on improving health and research outcomes and has built an experienced team and significant know-how in the development of whole genome amplification and array Comparative Genomic Hybridisation tools. It is this expertise that has gone into RHS’s EmbryoCellect™ kit.
RHS is located in the TechInSA Incubator in the heart of the Thebarton biotechnology precinct in Adelaide, South Australia. The company is listed on the Australian Stock Exchange (ASX).
- Aneuploidy detection in single cells using DNA array-based comparative genomic hybridization. Hu, D. G., Webb, G., & Hussey, N. Molecular Human Reproduction 2004, 10(4), 283–9.
- Gender determination and detection of aneuploidy in single cells using DNA array-based comparative genomic hybridization. Hu, D. G., Guan, X. Y., & Hussey, N. Methods in Molecular Medicine 2007, 132, 135–151.